natgillin/translations-raw huggingface dataset:
Patients may be counted in more than one row. dICH=intracranial haemorrhage. eClinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but &lt; 5 g/dL.
Bolniki so lahko našteti v več kot eni vrsti. d ICH=intracranial haemorrhage, intrakranialna krvavitev. e Klinično očitna krvavitev, povezana s padcem hemoglobina ≥ 3 g/dl vendar &lt; 5 g/dl.
Patients may be counted in more than one row. e ICH=intracranial haemorrhage. f Clinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but &lt; 5 g/dL.
Bolniki so lahko našteti v več kot eni vrsti. e ICH=intracranial haemorrhage, intrakranialna krvavitev. f Klinično očitna krvavitev, povezana s padcem hemoglobina ≥ 3 g/dl vendar &lt; 5 g/dl.
Patients may receive a second course of PDT a minimum of 90 days after the initial therapy; up to three courses of PDT (each injection separated by a minimum of 90 days) should be given to a previously treated segment which still shows HGD or to a new segment if the initial Barrett's segment was &gt; 7 cm in length.
Bolniki lahko dobijo drugo epizodo PDT najmanj 90 dni po začetnem zdravljenju; predhodno zdravljeni del, ki še vedno kaže HGD, ali novi del lahko prejme do tri epizode PDT (vsako injekcijo posebej čez najmanj 90 dni), če je bila dolžina začetnega segmenta Barrettovega požiralnika &gt; 7 cm.
Patients of weight &gt; 55 kg
Bolniki s telesno maso &gt; 55 kg
Patients of weight &gt; 55 kg
maso &gt; 55 kg
Patients over 60 years of age may be at greater risk for mild ( &gt; 3xULN) to severe ( &gt; 8xULN) elevation of ALT.
Tveganje za blago ( &gt; 3-kratna ZMN) do hudo ( &gt; 8-kratna ZMN) zvišanje vrednosti ALT je lahko večje pri bolnikih, starejših od 60 let.
Patients presenting end stage renal disease (creatinine clearance (CLCR &lt; 15 mL/min/1.73 m2), by their condition and the limited amount of data available should be treated with caution and monitored carefully during treatment (see sections 4.4 and 5.2).
Bolnike s končno fazo ledvične bolezni (očistek kreatinina je manjši od 15 ml/min/1.73 m2 ) je treba glede na njihovo stanje in zaradi maloštevilnih dostopnih podatkov zdraviti previdno in jih med zdravljenjem natančno kontrolirati (glejte poglavji 4.4 in 5.2).
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; or documented peripheral vascular disease.
V program ACTIVE so bili randomizirani bolniki, ki so imeli dokumentirano AF, tj. bodisi permanentno AF ali vsaj 2 epizodi intermitentne AF v zadnjih 6 mesecih ter vsaj enega od naslednjih dejavnikov tveganja: starost ≥ 75 let ali starost od 55 do 74 let in bodisi sladkorno bolezen, ki je zahtevala zdravljenje z zdravili, ali dokumentiran predhodni MI ali dokumentirano koronarno bolezen; zdravljenje zaradi sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako (TIA) ali sistemski embolus (ne v osrednjem živčevju); disfunkcijo levega prekata z iztisnim deležem levega prekata (LVEF) &lt; 45 %; ali dokumentirano bolezen perifernih žil.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; or documented peripheral vascular disease.
V program ACTIVE so bili randomizirani bolniki, ki so imeli dokumentirano AF, tj. bodisi permanentno AF ali vsaj 2 epizodi intermitentne AF v zadnjih 6 mesecih ter vsaj enega od naslednjih dejavnikov tveganja: starost  75 let ali starost od 55 do 74 let in bodisi sladkorno bolezen, ki je zahtevala zdravljenje z zdravili, ali dokumentiran predhodni MI ali dokumentirano koronarno bolezen; zdravljenje zaradi sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako (TIA) ali sistemski embolus (ne v osrednjem živčevju); disfunkcijo levega prekata z iztisnim deležem levega prekata (LVEF) &lt; 45 %; ali dokumentirano bolezen perifernih žil.
Patients received asparaginase at a dose of 10,000 U/m², adjusted to the current age of the patient at the time of administration ( &lt; 6 months: 6,700 U/m²; 6 – 12 months:
Bolniki so prejeli asparaginazo v odmerku 10.000 E/m², prilagojenem glede na trenutno starost bolnika v času dajanja ( &lt; 6 mesecev: 6.700 E/m²;
Patients receiving enzalutamide demonstrated a significantly higher total PSA response rate (defined as a ≥ 50% reduction from baseline), compared with patients receiving placebo, 78.0% versus 3.5% (difference = 74.5%, p &lt; 0.0001).
Pri bolnikih, ki so dobivali enzalutamid, je bila dokazana značilno višja skupna stopnja odziva PSA (opredeljeno kot ≥ 50 % zmanjšanje od izhodišča), v primerjavi z bolniki, ki so dobivali placebo, 78,0 % v primerjavi s 3,5 % (razlika = 74,5 %; p &lt; 0,0001).
Patients reported in all the 3 Phase III trials a clinically meaningful pain relief within the first hour of treatment with Zalviso (pain intensity difference to baseline and total pain response &gt; 1 NRS).
Bolniki so v vseh treh preizkušanjih 3. faze poročali o klinično pomembni ublažitvi bolečine v prvi uri zdravljenja z zdravilom Zalviso (razlika v intenzivnosti bolečine glede na izhodišče in skupen odziv na bolečino &gt; 1 NRS).
Patients requiring a titrated daily dose &gt; 8 mg buprenorphine /day may not find this regimen adequate.
Ta režim odmerjanja morda ne bo primeren za bolnike, ki potrebujejo prilagojen dnevni odmerek &gt; 8 mg buprenorfina/dan.
Patients requiring a titrated daily dose &gt; 8 mg buprenorphine /day may not find this regimen adequate.
Ta režim odmerjanja ne bo primeren za bolnike, ki potrebujejo prilagojen dnevni odmerek &gt; 8 mg buprenorfina/dan.
Patients requiring a titrated daily dose &gt; 8 mg buprenorphine/day may not find this regimen adequate.
Ta režim odmerjanja ne bo primeren za bolnike, ki potrebujejo prilagojen dnevni odmerek &gt; 8 mg buprenorfina/dan.
Patients requiring larger LDL-C reduction ( &gt; 60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.
Pri bolnikih, ki potrebujejo večje znižanje LDL-H ( &gt; 60 %), je zdravljenje mogoče začeti s 150 mg subkutano enkrat na 2 tedna ali s 300 mg subkutano enkrat na 4 tedne (mesečno).
Patients should be carefully assessed for their ability to tolerate lenalidomide in combination, with consideration to age, ISS stage III, ECOG PS≤2 or CLcr &lt; 60 mL/min (see section 4.2 and 4.8).
Bolnike morate skrbno oceniti glede njihove sposobnosti prenašanja lenalidomida v kombinaciji, z upoštevanjem starosti, stadija III ISS, ECOG PS≤2 ali CLcr &lt; 60 ml/min (glejte poglavji 4.2 in 4.8).
Patients should not be retreated with subsequent cycles of Abraxane until neutrophils recover to &gt; 1500 cells/mm3 and platelets recover to &gt; 100,000 cells/mm3 (see section 4.2).
Nadaljnjih ciklov zdravila Abraxane ne smete začeti, dokler se nevtrofilci ne vrnejo na vrednost &gt; 1.500 celic/mm3, trombociti pa na vrednost &gt; 100.000 celic/mm3 (glejte poglavje 4.2).
Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level
znova dobiti ciklusov docetaksela, dokler se število nevtrofilcev ne poveča na &gt; 1.500 celic/mm in
Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level &gt; 1,500 cells/mm3 and platelets recover to a level &gt; 100,000 cells/mm3.
Bolniki ne smejo znova dobiti ciklusov docetaksela, dokler se število nevtrofilcev ne poveča na &gt; 1.500 celic/mm3 in število trombocitov na &gt; 100.000 celic/mm3.
Patients studied were adults ( &gt; 18 years), with newly diagnosed differentiated papillary or follicular thyroid carcinoma, including papillary-follicular variant, characterised, principally (54 of 60), as T1-T2, N0-N1, M0 (TNM classification).
V študijo vključeni bolniki so bili odrasli ( &gt; 18 let), pri katerih je bil pred kratkim diagnosticiran diferencirani papilarni ali folikularni karcinom ščitnice, vključno s papilarnofolikularno različico, označen predvsem (54 od 60) kot T1-T2, N0-N1, M0 (TNM klasifikacija).
Patients transferring from a dose of &lt; 15 Units/kg imiglucerase were administered 15 Units/kg of velaglucerase alfa.
Bolniki, pri katerih je bil odmerek imigluceraze ob prehodu &lt; 15 enot/kg, so prejemali odmerek velagluceraze alfa 15 enot/kg.
Patients treated with ALIMTA and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Bolniki zdravljeni z zdravilom ALIMTA in cisplatinom so potrebovali manj transfuzij (16,4 % proti 28,9 %, p &lt; 0,001), transfuzij rdečih krvničk (16,1 % proti 27,3 %, p &lt; 0,001) in transfuzij krvnih ploščic (1,8 % proti 4,5 %, p = 0,002).
Patients treated with Kentera experienced a highly statistically significant decrease in the number of urinary incontinence episodes per day from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p &lt; 0.0001), as well as for the secondary endpoints: a decrease in the average daily urinary frequency (p=0.0017), and an increase in the average urine volume per void (p=0.0018).
Pri bolnikih, ki so prejemali zdravilo Kentera, se je število epizod urinarne inkontinence na dan statistično zelo pomembno zmanjšalo od izhodiščne točke do cilja študije (primarni cilj študije) v primerjavi s placebom (p &lt; 0,0001), enako pa velja tudi za sekundarna cilja študije: zmanjšanje povprečne dnevne urinarne frekvence (p = 0,0017) in povečanje povprečne prostornine urina na uriniranje (p = 0,0018).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4 % versus 28.9 %, p &lt; 0.001), red blood cell transfusions (16.1 % versus 27.3 %, p &lt; 0.001) and platelet transfusions (1.8 % versus 4.5 %, p = 0.002).
Bolniki zdravljeni s pemetreksedom in cisplatinom so potrebovali manj transfuzij (16,4 % proti 28,9 %, p &lt; 0,001), transfuzij rdečih krvničk (16,1 % proti 27,3 %, p &lt; 0,001) in transfuzij krvnih ploščic (1,8 % proti 4,5 %, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p = 0.002).
Bolniki zdravljeni s pemetreksedom in cisplatinom so potrebovali manj transfuzij (16,4 % proti 28,9 %, p &lt; 0,001), transfuzij rdečih krvničk (16,1 % proti 27,3 %, p &lt; 0,001) in transfuzij krvnih ploščic (1,8 % proti 4,5 %, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Bolniki zdravljeni s pemetreksedom in cisplatinom so potrebovali manj transfuzij (16,4 % proti 28,9 %, p &lt; 0,001), transfuzij rdečih krvničk (16,1 % proti 27,3 %, p &lt; 0,001) in transfuzij krvnih ploščic (1,8 % proti 4,5 %, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Bolniki zdravljeni s pemetreksedom in cisplatinom so potrebovali manj transfuzij (16,4% proti 28,9%, p &lt; 0,001), transfuzij rdečih krvničk (16,1% proti 27,3%, p &lt; 0,001) in transfuzij krvnih ploščic (1,8% proti 4,5%, p = 0,002).
Patients treated with Perjeta must have HER2-positive tumour status, defined as a score of 3+ by immunohistochemistry (IHC) and/or a ratio of ≥ 2.0 by in situ hybridisation (ISH) assessed by a validated test.
Bolniki, zdravljeni z zdravilom Perjeta, morajo imeti HER2-pozitivni tumor, imunohistokemično opredeljen kot 3+ in/ali razmerje pri in situ hibridizaciji (ISH) &gt; 2,0, opredeljeno z validiranim testom.
Patients treated with rilonacept experienced an 84% reduction in the mean symptom score in Part A compared to 13% for placebo-treated patients (p &lt; 0.0001).
Pri bolnikih, zdravljenih z rilonaceptom, so se povprečni izidi simptomov v delu A zmanjšali za 84 %, pri bolnikih, ki so prejemali placebo, pa za 13 % (p &lt; 0,0001).
Patients treated with trastuzumab emtansine should have HER2 positive tumour status, defined as a score of 3 + by immunohistochemistry (IHC) or a ratio of ≥ 2.0 by in situ hybridization (ISH) assessed by a CE-marked In Vitro Diagnostic (IVD) medical device.
Bolniki, zdravljeni s trastuzumabom emtanzinom, morajo imeti HER2-pozitivni tumor, imunohistokemično opredeljen kot 3+ ali razmerje pri in situ hibridizaciji (ISH) &gt; 2,0, določeno z validiranim testom (z diagnostičnim medicinskim pripomočkom in vitro z oznako CE).
Patients weighing &lt; 60 kg
Bolniki, ki tehtajo &lt; 60 kg
Patients weighing &lt; 60 kg should have a reduced maintenance dose of 5mg
Bolniki s telesno maso &lt; 60 kg morajo jemati nižji vzdrževalni odmerek 5 mg.
Patients were considered to have impaired bone marrow reserve if they had any of the following: prior myeloablative therapy with stem cell support; prior external beam radiation to &gt; 25% of active marrow; a platelet count &lt; 100,000 cells/mm3; or neutrophil count &lt; 1,500 cells/mm3.
Veljalo je, da so imeli bolniki prizadeto rezervo kostnega mozga, če so imeli kaj od naslednjega: predhodno ablacijo kostnega mozga s podporo matičnih celic; predhodno obsevanje, ki je zajelo več kot 25 % delujočega kostnega mozga; število trombocitov &lt; 100.000 celic/mm3; število nevtrofilnih celic &lt; 1.500 celic/mm3.
Patients were eligible for retreatment based upon central subfield retinal thickness &gt; 175 microns by optical coherence tomography (OCT) or upon investigators interpretation of the OCT for any evidence of residual retinal edema consisting of intraretinal cysts or any regions of increased retinal thickening within or outside of the central subfield.
O ponovnem zdravljenju bolnikov se je odločalo na podlagi, če je bila debelina centralnega podpolja očesne mrežnice, izmerjena z optično koherenčno tomografijo (OKT), &gt; 175 mikronov, ali pa če so raziskovalci pri OKT opazili znake ostankov retinalnega edema v obliki intraretinalnih cist ali območij povečane zadebelitve mrežnice znotraj ali zunaj centralnega podpolja.
Patients were enrolled with CD4 counts
Bolnice so imele ob sprejemu v raziskavo število CD4 &lt; 250 celic/mm3, bolniki pa
Patients were excluded if they had severe hepatic impairment, severe renal impairment (creatinine clearance &lt; 30ml/min), low body weight ( &lt; 50kg), active cancer, symptomatic PE or a recent history of DVT/PE ( &lt; 6 months) or superficial-vein thrombosis ( &lt; 90 days), or superficial-vein thrombosis associated with sclerotherapy or a complication of an IV line, or they were at high risk of bleeding.
Bolniki so bili izključeni, če so imeli hudo okvaro jeter, hudo okvaro ledvic (očistek kreatinina &lt; 30 ml/min), majhno telesno maso ( &lt; 50 kg), aktivnega raka, simptomatsko pljučno embolijo ali nedavno anamnezo globoke venske tromboze/pljučne embolije ( &lt; 6 mesecev) ali povrhnje venske tromboze ( &lt; 90 dni) ali povrhnjo vensko trombozo, povezano s skleroterapijo ali kot zaplet intravenske linije, ali če so imeli veliko tveganje krvavitve.
Patients were instructed to maintain a low-fat diet ( &lt; 20% calories from fat) and their lipid-lowering therapies at study entry, including apheresis if applicable, from 6 weeks prior to baseline through at least Week 26.
Bolnikom so ob vključitvi v študijo naročili, naj vzdržujejo dieto z majhnim vnosom maščob ( &lt; 20 % kalorij iz maščob) in zdravljenje za zniževanje ravni lipidov, vključno z aferezo, če je primerno, od 6 tednov pred izhodiščem do zadnjega, 26. tedna.
Patients were randomised to receive either anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) or fluconazole (800 mg intravenous loading dose followed by 400 mg intravenous daily), and were stratified by APACHE II score (≤20 and &gt; 20) and the presence or absence of neutropaenia.
Bolnike so randomizirali na prejemanje bodisi anidulafungina (200 mg intravenski polnilni odmerek, ki mu je sledila aplikacija po 100 mg na dan intravensko) bodisi flukonazola (800 mg intravenski polnilni odmerek, ki mu je sledila aplikacija po 400 mg na dan intravensko).
Patients were required to be &gt; 18 years of age with active RA diagnosed according to ACR criteria who had at least 8 tender and 6 swollen joints at baseline.
Bolniki so morali biti starejši od 18 let in imeti aktiven revmatoidni artritis, diagnosticiran po merilih ACR, izhodiščno so imeli vsaj osem bolečih in šest oteklih sklepov.
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to &lt; 6 years, 6 to &lt; 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m2 dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two non- protease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Bolnike z izhodiščno koncentracijo HIV-1 RNA najmanj 1500 kopij/ml so stratificirali po starosti (2 do &lt; 6 let, 6 do &lt; 12 let in 12 do 18 let) in jih naključno razvrstili v zdravljenje z enim od naslednjih dveh režimov odmerjanja tipranavirja ob ritonavirju: odmerek po 375 mg/m2 in 150 mg/m2 primerjan z odmerkom po 290 mg/m2 in 115 mg/m2 ob osnovnem zdravljenju z najmanj dvema protiretrovirusnima zdraviloma, ki nista zaviralca proteaze, optimiziranem s testiranjem genotipske odpornosti.
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to &lt; 6 years, 6 to &lt; 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m2 dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two non- protease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Bolnike z izhodiščno koncentracijo HIV-1 RNA najmanj 1500 kopij/ml so stratificirali po starosti (2 do &lt; 6 let, 6 do &lt; 12 let in 12 do 18 let) in jih naključno razvrstili v zdravljenju z enim od naslednjih dveh režimov odmerjanja tipranavirja ob ritonavirju: odmerek po 375 mg/m2 in 150 mg/m2 primerjan z odmerki po 290 mg/m2 in 115 mg/m2 ob osnovnem zdravljenju z najmanj dvema protiretrovirusnima zdraviloma, ki nista zaviralca proteaze, optimiziranem s testiranjem genotipske odpornosti.
Patients were required to have an HIV-1 RNA &lt; 50 copies/ml and CD4 count &gt; 300 cells/mm3 at screening.
Bolniki so morali imeti na presejalnem pregledu &lt; 50 kopij RNK HIV-1/ml, število celic CD4 ≥ 300 celic/mm3.
Patients were stratified according to region, iNHL subtype (follicular versus non-follicular), rituximab-refractory type (whether refractory to prior rituximab monotherapy or rituximab in combination with chemotherapy) and the number of prior therapies (≤2 versus &gt; 2).
Bolnike so stratificirali glede na regijo, podvrsto iNHL (folikularni ali nefolikularni), vrsto refraktarnosti na rituksimab (refraktaren na predhodno monoterapijo z rituksimabom ali na rituksimab v kombinaciji s kemoterapijo) in število predhodnih zdravljenj (≤ 2 ali &gt; 2).
Patients were stratified at randomisation by age ( 75 vs. &gt; 75 years) and stage (ISS; Stages I and II vs. stage III).
Pri randomizaciji so bolnike stratificirali po starosti ( 75 proti &gt; 75 let) in stadiju (ISS; stadija I in II proti stadiju III).
Patients were stratified at randomization by age (≤75 versus &gt; 75 years), stage (ISS Stages I and II versus Stage III), and country.
Pri randomizaciji so bolnike stratificirali po starosti (≤75 proti &gt; 75 let), stadiju (ISS stadija I in II proti stadiju III), in državi.
Patients were stratified by hemoglobin level (≤13 g/dL vs. &gt; 13 g/dL for males and ≤11.5 g/dL vs &gt; 11.5 g/dL for females) and corrected serum calcium (≥10 mg/dL vs. &lt; 10 mg/dL).
Bolnike so stratificirali po koncentraciji hemoglobina (≤ 13 g/dl proti &gt; 13 g/dl za moške in ≤ 11,5 g/dl proti &gt; 11,5 g/dl za ženske) in popravljenem serumskem kalciju (≥ 10 mg/dl proti &lt; 10 mg/dl).
Patients were stratified with respect to duration of glucocorticoid use prior to randomisation (≤ 3 months versus &gt; 3 months).
Bolnike so stratificiratli v dve podskupini glede na trajanje zdravljenja z glukokortikoidi pred randomizacijo (≤ 3 mesece oziroma &gt; 3 mesece).
Patients were to have at least one risk factor (including age, hypertension, diabetes, prior cerebrovascular accident, left atrium diameter ≥50 mm or LVEF &lt; 0.40) together with AF/AFL and sinus rhythm both documented within the last 6 months.
Bolniki so morali imeti vsaj en dejavnik tveganja (vključno s starostjo, hipertenzijo, sladkorno boleznijo, predhodnim cerebrovaskularnim inzultom, premerom levega preddvora ≥ 50 mm ali LVEF &lt; 0,40) ter AF/AU in sinusni ritem, oboje dokumentirano v zadnjih 6 mesecih.
Patients were virologically suppressed (HIV-1 RNA &lt; 50 copies/mL) for at least 6 months before switching.
Bolniki so imeli pred prehodom virusno supresijo (HIV-1 RNA &lt; 50 kopij/ml) vsaj 6 mesecev.
Patients who commence delamanid with serum albumin &lt; 3.4 g/dL or experience a fall in serum albumin into this range during treatment should receive very frequent monitoring of ECGs throughout the full delamanid treatment period.
&lt; 3,4 mg/dl ali ki so med zdravljenjem doživeli upad serumskega albumina v ta razpon, je treba zelo redno spremljati s pomočjo EKG-ja ves čas zdravljenja z delamanidom.
Patients who experience either febrile neutropenia, neutrophils &lt; 500 cells/mm3 for more than 1 week, severe or cumulative cutaneous reactions, or other Grade 3 or 4 non-haematological toxicities during docetaxel treatment should have treatment withheld until resolution of the toxicity.
Pri bolnikih, pri katerih se med zdravljenjem z docetakselom pojavijo bodisi febrilna nevtropenija, število nevtrofilcev &lt; 500 celic/mm3, ki traja več kot 1 teden, hude kožne reakcije ali druge nehematološke toksičnosti razreda 3 ali 4, je treba zdravljenje prekiniti, dokler toksičnost ne mine.
Patients who experience severe neutropenia (neutrophil count &lt; 500 cells/mm3 for a week or longer) or severe sensory neuropathy during Abraxane therapy should have the dose reduced to 220 mg/m2 for subsequent courses.
Pri bolnikih, ki imajo med zdravljenjem z zdravilom Abraxane hudo nevtropenijo (število nevtrofilcev &lt; 500 celic/mm3 v obdobju enega tedna ali dlje) ali hudo senzorično nevropatijo, je treba za vsa nadaljnja zdravljenja odmerek zmanjšati na 220 mg/m2.
Patients who had 3 consecutive sUA levels &gt; 6.0 mg/dL were withdrawn.
Bolnike, ki so imeli 3 zaporedne vrednosti sUA na ravni &gt; 6,0 mg/dl, so iz raziskave izključili.
Patients who had 3 consecutive sUA levels &gt; 6.0 mg/dL were withdrawn.
Bolnike, ki so imeli 3 zaporedne vrednosti sUA na ravni &gt; 6,0 mg/dl, so izključili iz raziskave.